The Paired Box-8/Peroxisome Proliferator-Activated Receptor-γ Oncogene in Thyroid Tumorigenesis | Zendy

Honey V. Reddi | Zendy; Bryan McIver | Zendy; Stefan K. Grebe | Zendy; Norman L. Eberhardt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Paired Box-8/Peroxisome Proliferator-Activated Receptor-γ Oncogene in Thyroid Tumorigenesis

Author(s) -

Honey V. Reddi,

Bryan McIver,

Stefan K. Grebe,

Norman L. Eberhardt

Publication year - 2006

Publication title -

endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.674

H-Index - 257

eISSN - 1945-7170

pISSN - 0013-7227

DOI - 10.1210/en.2006-0926

Subject(s) - thyroid cancer , thyroid , thyroid carcinoma , peroxisome proliferator activated receptor , carcinogenesis , cancer research , transcription factor , medicine , biology , endocrinology , nuclear receptor , oncogene , cancer , receptor , gene , cell cycle , genetics

The American Cancer Society estimates 30,180 new cases of thyroid cancer in the United States in 2006. Of all thyroid cancers, 15–20% are follicular thyroid carcinoma (FTC), making this the second most common thyroid malignancy (after papillary carcinoma). A proportion of FTC has been found to be associated with a chromosomal translocation, t (2, 3)(q13;p25), which fuses the thyroid-specific transcription factor paired box-8 with the peroxisome proliferator-activated receptor-γ nuclear receptor, a ubiquitously expressed transcription factor. This fusion event causes expression of a paired box-8/peroxisome proliferator-activated receptor-γ fusion protein (PPFP). PPFP is detected in approximately 30% of FTC. In this report we review data on the role of PPFP in FTC, its mechanism of oncogenesis, and PPFP targeting as a strategy in thyroid cancer treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research